The drug pricing negotiations for ‘Ceprotin (Protein C Concentrate (Human))’ a new drug for severe congenital protein C deficiency supplied by Takeda Pharmaceuticals Korea, fell through. On the other hand, the company reached an agreement and completed negotiations to expand the reimbursement for the ovarian cancer treatment Zejula Cap.

According to industry sources on the 24th, the National Health Insurance Service announced so while updating the list of drugs that have completed drug price negotiations.

Ceprotin passed the NHIS’s Drug Reimbursement Evaluation Committee in June and began negotiating with the NHIS in July, which is the final step to a drug’s reimbursement in Korea.